T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer

Osimertinib prolongs progression-free survival (PFS) in patients with metastatic, epidermal growth factor receptor (EGFR) T790M-mutated, non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitor (TKI) therapy. We investigated the utility of T790M mutant copy number quantific...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jacky Yu-Chung, Ho, James Chung-Man, Wong, Kam-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021335/
https://www.ncbi.nlm.nih.gov/pubmed/29963252
http://dx.doi.org/10.18632/oncotarget.25332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021335/
https://www.ncbi.nlm.nih.gov/pubmed/29963252
http://dx.doi.org/10.18632/oncotarget.25332

Ejemplares similares